Enanta Pharmaceuticals Inc expected to post a loss of $1.59 a share - Earnings Preview

Enanta Pharmaceuticals

03/02/2023 21:47

* Enanta Pharmaceuticals Inc  ENTA.OQ   ENTA.O  is expected
to show a fall in quarterly revenue when it reports  results on
February 7. 
    * The Watertown Massachusetts-based  company is expected to
report
 a 18.4% decrease in revenue to $22.569 million from $27.65
million a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Enanta
Pharmaceuticals
Inc is for a loss of $1.59 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Enanta
Pharmaceuticals Inc is $61​, above​ its last closing price
of $52.75. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -1.40       -1.35      -1.27     Beat    6.1
 Jun. 30 2022  -1.46       -1.39      -1.53     Missed  -10.4
 Mar. 31 2022  -1.36       -1.43      -1.63     Missed  -14.3​
 Dec. 31 2021  -1.07       -1.08      -1.48     Missed  -36.6
 ​​Sep.        -1.17       -1.22      -1.22     Met     0.2
 30 2021                                                
 Jun. 30 2021  -1.32       -1.28      -1.19     Beat    6.9​
 Mar. 31 2021  -1.04       -0.98      -1.09     Missed  -11
 Dec. 31 2020  -0.68       -0.74      -0.41     Beat    44.6
 This summary was machine generated February 3 at 21:47 GMT.  All
figures in US dollars  unless otherwise stated